Item Type | Name |
Concept
|
Cardiovascular Diseases
|
Academic Article
|
Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat: a randomized controlled trial.
|
Academic Article
|
Effects of continuous estrogen and estrogen-progestin replacement regimens on cardiovascular risk markers in postmenopausal women.
|
Academic Article
|
Efficacy of over-the-counter nutritional supplements.
|
Academic Article
|
Risk of cardiovascular disease and sudden death in schizophrenia.
|
Academic Article
|
Cardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin Replacement Study follow-up (HERS II).
|
Academic Article
|
A cross-sectional study of lipids and ApoC levels in Alzheimer's patients with and without cardiovascular disease.
|
Academic Article
|
C-reactive protein as a predictor of cardiovascular risk in a population with a high prevalence of diabetes: the Strong Heart Study.
|
Academic Article
|
Global risk management in patients with type 2 diabetes mellitus.
|
Academic Article
|
Use of a treatment algorithm to achieve NCEP ATP III goals with atorvastatin.
|
Academic Article
|
Effect of pioglitazone compared with glimepiride on carotid intima-media thickness in type 2 diabetes: a randomized trial.
|
Academic Article
|
Effects of a reduced-glycemic-load diet on body weight, body composition, and cardiovascular disease risk markers in overweight and obese adults.
|
Academic Article
|
Prescription omega-3 fatty acids and their lipid effects: physiologic mechanisms of action and clinical implications.
|
Academic Article
|
Effects of high-fiber oat and wheat cereals on postprandial glucose and lipid responses in healthy men.
|
Academic Article
|
Application of recent definitions of the metabolic syndrome to survey data from the National Cholesterol Education Program Evaluation Project Utilizing Novel E-Technology (NEPTUNE II).
|
Academic Article
|
Should every patient with diabetes receive a statin?
|
Academic Article
|
The editor's roundtable: lipid management beyond statins-reducing residual cardiovascular risk.
|
Academic Article
|
Overview of prevention and treatment of atherosclerosis with lipid-altering therapy for pharmacy directors.
|
Academic Article
|
Combination therapy in the management of complex dyslipidemias.
|
Academic Article
|
Lipoprotein management in patients with cardiometabolic risk: consensus conference report from the American Diabetes Association and the American College of Cardiology Foundation.
|
Academic Article
|
The editor's roundtable: the JUPITER trial--initial results and clinical implications.
|
Academic Article
|
ACCF/AHA/ACP 2009 competence and training statement: a curriculum on prevention of cardiovascular disease: a report of the American College of Cardiology Foundation/American Heart Association/American College of Physicians Task Force on Competence and Training (Writing Committee to Develop a Competence and Training Statement on Prevention of Cardiovascular Disease): developed in collaboration with the American Academy of Neurology; American Association of Cardiovascular and Pulmonary Rehabili...
|
Academic Article
|
A genetic and epidemiologic study of cardiovascular disease in Alaska natives (GOCADAN): design and methods.
|
Academic Article
|
Combination therapy with ezetimibe and simvastatin to achieve aggressive LDL reduction.
|
Academic Article
|
Effect of ACAT inhibition on the progression of coronary atherosclerosis.
|
Academic Article
|
Low high-density lipoprotein cholesterol and increased cardiovascular disease risk: an analysis of statin clinical trials.
|
Academic Article
|
Underappreciated opportunities for low-density lipoprotein management in patients with cardiometabolic residual risk.
|
Academic Article
|
Targeting high-density lipoprotein cholesterol in the management of cardiovascular disease.
|
Academic Article
|
Usefulness of increased skin cholesterol to identify individuals at increased cardiovascular risk (from the Predictor of Advanced Subclinical Atherosclerosis study).
|
Academic Article
|
Lipoprotein management in patients with cardiometabolic risk: consensus statement from the American Diabetes Association and the American College of Cardiology Foundation.
|
Academic Article
|
Consensus panel recommendation for incorporating lipoprotein-associated phospholipase A2 testing into cardiovascular disease risk assessment guidelines.
|
Academic Article
|
High-dose statin therapy: benefits and safety in aggressive lipid lowering.
|
Academic Article
|
Statin and ezetimibe combination therapy in cardiovascular disease.
|
Academic Article
|
Flushing profile of extended-release niacin/laropiprant versus gradually titrated niacin extended-release in patients with dyslipidemia with and without ischemic cardiovascular disease.
|
Academic Article
|
Counterpoint: Low-density lipoprotein cholesterol goals in patients with diabetes are adequately based on evidence.
|
Academic Article
|
High-density lipoproteins: marker of cardiovascular risk and therapeutic target.
|
Academic Article
|
Clinical utility of inflammatory markers and advanced lipoprotein testing: advice from an expert panel of lipid specialists.
|
Academic Article
|
Review of the evidence for the clinical utility of lipoprotein-associated phospholipase A2 as a cardiovascular risk marker.
|
Academic Article
|
The use of high-sensitivity assays for C-reactive protein in clinical practice.
|
Academic Article
|
Efficacy and safety of dalcetrapib in type 2 diabetes mellitus and/or metabolic syndrome patients, at high cardiovascular disease risk.
|
Academic Article
|
Cardio-diabetes: special considerations for the patient with diabetes and cardiovascular disease. Introduction.
|
Academic Article
|
Cardiovascular risk factors in a patient with diabetes mellitus and coronary artery disease: therapeutic approaches to improve outcomes: perspectives of a preventive cardiologist.
|
Academic Article
|
Type 2 diabetes and cardiovascular disease: reducing the risk.
|
Academic Article
|
Apolipoprotein measurements: is more widespread use clinically indicated?
|
Academic Article
|
ACCF/AHA/ACP 2009 competence and training statement: a curriculum on prevention of cardiovascular disease: a report of the American College of Cardiology Foundation/American Heart Association/American College of Physicians Task Force on Competence and Training (Writing Committee to Develop a Competence and Training Statement on Prevention of Cardiovascular Disease): developed in collaboration with the American Academy of Neurology; American Association of Cardiovascular and Pulmonary Rehabili...
|
Academic Article
|
Efficacy and tolerability of atorvastatin/fenofibrate fixed-dose combination tablet compared with atorvastatin and fenofibrate monotherapies in patients with dyslipidemia: a 12-week, multicenter, double-blind, randomized, parallel-group study.
|
Academic Article
|
The incremental value of lipids and inflammatory biomarkers in determining residual cardiovascular risk.
|
Academic Article
|
Treatment of the elderly with 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors: focus on drug interactions.
|
Academic Article
|
Assessing cardiovascular risks versus clinical benefits of atypical antipsychotic drug treatment.
|
Academic Article
|
The role of cardiovascular risk factors in Alzheimer's disease.
|
Academic Article
|
Antipsychotic-induced weight gain and metabolic abnormalities: implications for increased mortality in patients with schizophrenia.
|
Academic Article
|
Cardiovascular disease among Alaska Natives: a review of the literature.
|
Academic Article
|
Impaired diurnal blood pressure variation and all-cause mortality.
|
Academic Article
|
Dysfunctional HDL: a novel important diagnostic and therapeutic target in cardiovascular disease?
|
Academic Article
|
Low-density lipoprotein cholesterol, non-high-density lipoprotein, apolipoprotein, or low-density lipoprotein particle: what should clinicians measure?
|
Academic Article
|
Changes in cardiovascular risk associated with phentermine and topiramate extended-release in participants with comorbidities and a body mass index =27 kg/m(2).
|
Academic Article
|
Diagnosis and treatment of familial hypercholesterolaemia.
|
Academic Article
|
AACE comprehensive diabetes management algorithm 2013.
|
Academic Article
|
Underappreciated opportunities for high-density lipoprotein particles in risk stratification and potential targets of therapy.
|
Academic Article
|
Combination therapy with statins: who benefits?
|
Academic Article
|
Genetics and causality of triglyceride-rich lipoproteins in atherosclerotic cardiovascular disease.
|
Academic Article
|
High-density lipoproteins: a consensus statement from the National Lipid Association.
|
Academic Article
|
Mipomersen, an apolipoprotein B synthesis inhibitor, reduces atherogenic lipoproteins in patients with severe hypercholesterolemia at high cardiovascular risk: a randomized, double-blind, placebo-controlled trial.
|
Academic Article
|
A highly bioavailable omega-3 free fatty acid formulation improves the cardiovascular risk profile in high-risk, statin-treated patients with residual hypertriglyceridemia (the ESPRIT trial).
|
Academic Article
|
[Official document of the International Society of Atherosclerosis: general recommendations for treatment of dyslipidemia. Executive summary].
|
Academic Article
|
Potential impact of dipeptidyl peptidase-4 inhibitors on cardiovascular pathophysiology in type 2 diabetes mellitus.
|
Academic Article
|
Statin intolerance - an attempt at a unified definition. Position paper from an International Lipid Expert Panel.
|
Academic Article
|
Effects of omega-3 carboxylic acids on lipoprotein particles and other cardiovascular risk markers in high-risk statin-treated patients with residual hypertriglyceridemia: a randomized, controlled, double-blind trial.
|
Academic Article
|
Role of Ezetimibe in Lipid-Lowering and Cardiovascular Disease Prevention.
|
Academic Article
|
Triglyceride-lowering therapies reduce cardiovascular disease event risk in subjects with hypertriglyceridemia.
|
Academic Article
|
AACE/ACE comprehensive diabetes management algorithm 2015.
|
Academic Article
|
Using Discordance in Monozygotic Twins to Understand Causality of Cardiovascular Disease Risk Factors.
|
Academic Article
|
Reductions in Atherogenic Lipids and Major Cardiovascular Events: A Pooled Analysis of 10 ODYSSEY Trials Comparing Alirocumab With Control.
|
Academic Article
|
Omega-3 carboxylic acids monotherapy and combination with statins in the management of dyslipidemia.
|
Academic Article
|
AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY GUIDELINES FOR MANAGEMENT OF DYSLIPIDEMIA AND PREVENTION OF CARDIOVASCULAR DISEASE - EXECUTIVE SUMMARYComplete Appendix to Guidelines available at http://journals.aace.com.
|
Academic Article
|
The effect of omega-3 carboxylic acids on apolipoprotein CIII-containing lipoproteins in severe hypertriglyceridemia.
|
Academic Article
|
AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY GUIDELINES FOR MANAGEMENT OF DYSLIPIDEMIA AND PREVENTION OF CARDIOVASCULAR DISEASE.
|
Academic Article
|
Evolution of Omega-3 Fatty Acid Therapy and Current and Future Role in the Management of Dyslipidemia.
|
Academic Article
|
Assessment of omega-3 carboxylic acids in statin-treated patients with high levels of triglycerides and low levels of high-density lipoprotein cholesterol: Rationale and design of the STRENGTH trial.
|
Academic Article
|
Omega-3 carboxylic acids in patients with severe hypertriglyceridemia: EVOLVE II, a randomized, placebo-controlled trial.
|
Academic Article
|
Lower On-Treatment Low-Density Lipoprotein Cholesterol and Major Adverse Cardiovascular Events in Women and Men: Pooled Analysis of 10 ODYSSEY Phase 3 Alirocumab Trials.
|
Academic Article
|
How Genomics Is Personalizing the Management of Dyslipidemia and Cardiovascular Disease Prevention.
|
Academic Article
|
Efficacy and Safety of Alirocumab in High-Risk Patients With Clinical Atherosclerotic Cardiovascular Disease and/or Heterozygous Familial Hypercholesterolemia (from 5 Placebo-Controlled ODYSSEY Trials).
|
Academic Article
|
?-6 Polyunsaturated Fatty Acids and Cardiometabolic Health: Current Evidence, Controversies, and Research Gaps.
|
Academic Article
|
Clinical trials.
|
Academic Article
|
Lipoprotein(a) reductions from PCSK9 inhibition and major adverse cardiovascular events: Pooled analysis of alirocumab phase 3 trials.
|
Academic Article
|
Associations between lower levels of low-density lipoprotein cholesterol and cardiovascular events in very high-risk patients: Pooled analysis of nine ODYSSEY trials of alirocumab versus control.
|
Academic Article
|
Recent advances and emerging therapies in management of dyslipidemias.
|
Academic Article
|
Effect of High-Dose Omega-3 Fatty Acids vs Corn Oil on Major Adverse Cardiovascular Events in Patients at High Cardiovascular Risk: The STRENGTH Randomized Clinical Trial.
|
Academic Article
|
Ziltivekimab for Treatment of Anemia of Inflammation in Patients on Hemodialysis: Results from a Phase 1/2 Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial.
|
Academic Article
|
How I treat statin-associated side effects in an outpatient setting.
|
Academic Article
|
Consensus Statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the Management of Dyslipidemia and Prevention of Cardiovascular Disease Algorithm - 2020 Executive Summary.
|
Academic Article
|
Lipid measurements in the management of cardiovascular diseases: Practical recommendations a scientific statement from the national lipid association writing group.
|